Search research articles
Contact Us
Filters
Showing results (271-280 of 274) with videos related to
Page
of 28
Sort By:
You have reached the last page of results.
This site can display upto 274 results.
Nature
|
March 7, 1996
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
M Verheij, R Bose, X H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
C H Barcenas, S A Hurvitz, J A Di Palma, et al.
Anesthesiology
|
January 26, 2018
Simulation-based Assessment to Reliably Identify Key Resident Performance Attributes
Richard H Blum, Sharon L Muret-Wagstaff, John R Boulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K Jhaveri, L D Eli, H Wildiers, et al.
Page
of 28
Search research articles
Search
Showing results (271-280 of 274) with videos related to
Sort By:
Page
of 28
You have reached the last page of results.
This site can display upto 274 results.
Nature
|
March 7, 1996
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
M Verheij, R Bose, X H Lin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
C H Barcenas, S A Hurvitz, J A Di Palma, et al.
Anesthesiology
|
January 26, 2018
Simulation-based Assessment to Reliably Identify Key Resident Performance Attributes
Richard H Blum, Sharon L Muret-Wagstaff, John R Boulet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K Jhaveri, L D Eli, H Wildiers, et al.
Page
of 28